Propofol


Generic Medicine Info
Contraindications
Sedation in ICU setting in children <16 years.
Special Precautions
Patient with lipid metabolism disorders such as hypertriglyceridaemia or pancreatitis, or risk of fat overload; cardiac impairment; pulmonary insufficiency or respiratory depression; increased intracranial pressure or impaired cerebral circulation; hypovolaemia, unstable haemodynamics, abnormal low vascular tone (e.g. sepsis); risk factors for PRIS (e.g. decreased oxygen delivery, sepsis, serious cerebral injury). Patient predisposed to zinc deficiency (e.g. diarrhoea, major sepsis, burns). ASA grade 3 or 4, debilitated and epileptic patient. Renal and hepatic impairment. Children and elderly. Pregnancy and lactation. . Avoid abrupt discontinuation; taper infusion dose to prevent withdrawal (for prolonged infusions). Not recommended for obstetric anaesthesia including caesarean section deliveries. Patient Counselling This drug may impair ability to drive or operate machinery. Monitoring Parameters Monitor cardiac input, blood pressure, oxygen saturation (during monitored anaesthesia care sedation); ABG (prolonged infusions). Monitor signs and symptoms of PRIS. Monitor serum triglycerides prior to initiation of therapy for ICU sedation and every 3-7 days thereafter; zinc level after 5 days of treatment.
Adverse Reactions
Significant: ECG effects (e.g. QT shortening/prolongation), hypertriglyceridaemia, hypotension, injection-site reaction, perioperative myoclonus (e.g. convulsions, opisthotonos), involuntary movement, Rarely, postoperative unconsciousness with or without an increase in muscle tone, anaphylaxis, hypersensitivity reactions. Cardiac disorders: Cardiac arrhythmia, low cardiac output, tachycardia. Gastrointestinal disorders: Nausea and vomiting. Metabolism and nutrition disorders: Respiratory acidosis. Nervous system disorders: Headache. Psychiatric disorders: Depression, confusion. Respiratory, thoracic and mediastinal disorders: Cough, laryngospasm. Skin and subcutaneous tissue disorders: Rash, pruritus. Vascular disorders: Hypertension.
Potentially Fatal: Propofol-related infusion syndrome (PRIS) (e.g. lactic acidosis, hyperlipidaemia, hyperkalaemia, rhabdomyolysis). Abuse and dependence.
Drug Interactions
Additive sedative/anaesthetic and cardiorespiratory depressant effect with other CNS depressants. Profound hypotension with rifampicin. Valproate may increase serum levels of propofol.
CIMS Class
Anaesthetics- local & general
ATC Classification
N01AX10 - propofol ; Belongs to the class of other general anesthetics.
Disclaimer: This information is independently developed by CIMS based on propofol from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in